Find out more about how this website uses cookies to enhance your browsing experience.
Accept Cookies
Breast cancer is the most frequent cancer in women in the United States and the second greatest cause of cancer-related fatalities. An estimated 270,000 women and a much lower number of males are diagnosed with it each year. It's usually highly curable when found early on.
Some women with early-stage breast cancer linked to specific genetic flaws may have more options thanks to a promising new type of tailored treatment. (Cancers in the early stages have not spread to other organs or tissues in the body.)
What does the BRCA gene do?
BRCA genes refer to BRCA1 and BRCA2 genes, which you may have heard of. BRCA genes normally assist in the repair of DNA (genetic code) damage that occurs on a regular basis in cells throughout the human body.
BRCA mutations are aberrant abnormalities in these genes that are handed down from one generation to the next. When a person has a BRCA mutation, their body is less able to repair ordinary DNA damage to cells. This cumulative cell damage could pave the way for cancer to develop. A person with a BRCA1 or BRCA2 mutation or both is more likely to develop cancers of the breast, ovaries, prostate, or pancreatic, as well as melanoma. Other gene mutations and other factors can influence a person's breast cancer risk.
BRCA gene mutations are found in just 3% to 5% of all breast cancer patients. BRCA mutations, on the other hand, are more common among patients with triple-negative breast cancer (TNBC), Ashkenazi Jewish heritage, a significant family history of breast and/or ovarian cancer, and younger women with breast cancer.
Read more How long does your period last?
Breast cancer types and inherited BRCA mutations
Women with BRCA gene mutations are more likely to develop certain forms of breast cancer.
Breast cancer cells that are fueled by the hormone oestrogen but not by a protein called HER2 are more likely to form in women who have a BRCA2 mutation (human epidermal growth factor 2)
Triple-negative breast cancer (ER-/PR-/HER2-): Women with a BRCA1 mutation are more likely to develop triple-negative breast cancer (ER-/PR-/HER2-) cancer cells that aren't fuelled by estrogen, progesterone, or HER2.
Knowing what causes different types of breast cancer to grow aids scientists in developing novel treatments and clinicians in deciding which medicines to use to delay or stop tumor growth. This frequently necessitates a combination of treatments.
A novel treatment for early-stage BRCA-related breast malignancies has been developed
Women with early-stage breast cancer and hereditary BRCA1/BRCA2 mutations were included in the Olympic trial. Despite normal treatments, they were all at a high risk of breast cancer recurrence.
Participants in the study had received typical breast cancer treatments, including:
a procedure (a mastectomy or lumpectomy)
treatment with chemo (given either before or after surgery)
Endocrine therapy, which is a hormone-blocking medication, is a possibility.
For one year, they were randomly allocated to consume olaparib or placebo (sugar tablets) pills twice a day.
Read more What scientist have Discovered About Estrogen and Physical Activity
Olaparib is a PARP inhibitor, which is a type of medication. PARP (poly adenosine diphosphate-ribose polymerase) is a DNA-repair enzyme. When this enzyme is blocked in BRCA-mutated cancer cells, the cells perish due to increased DNA damage.
The New England Journal of Medicine published the findings of this investigation. Women who got olaparib were less likely than those who received a placebo to have their breast cancer relapse or metastasis (spread to other organs or tissues). After two and a half years of follow-up, slightly more than 85 percent of women who took olaparib were alive and had no cancer recurrence or new second malignancy, compared to 77 percent of women who received placebo.
In addition, the researchers calculated that after three years:
With olaparib, the chances of cancer not spreading to distant organs or tissues where roughly 88 percent, compared to 80 percent with placebo.
The olaparib-treated group had a 92 percent chance of survival, while the placebo group had an 88 percent chance.
Low white cell count, low red cell count, and weariness are all adverse effects of olaparib. These had a slim possibility of coming to fruition.
The bottom line
The FDA has already approved Olaparib for the treatment of BRCA-related malignancies of the ovaries, pancreatic, and prostate, as well as metastatic breast cancer. Based on the findings of this study, FDA clearance for BRCA-related early-stage breast cancer is expected soon. These findings show that taking olaparib for a year after finishing standard therapy could be a suitable option for women with early-stage breast cancer who have an inherited BRCA gene mutation and are at high risk of cancer recurrence and metastasis.
© 2024. All rights reserved.
Breast cancer is the most frequent cancer in women in the United States and the second greatest cause of cancer-related fatalities. An estimated 270,000 women and a much lower number of males are diagnosed with it each year. It's usually highly curable when found early on.
Some women with early-stage breast cancer linked to specific genetic flaws may have more options thanks to a promising new type of tailored treatment. (Cancers in the early stages have not spread to other organs or tissues in the body.)
What does the BRCA gene do?
BRCA genes refer to BRCA1 and BRCA2 genes, which you may have heard of. BRCA genes normally assist in the repair of DNA (genetic code) damage that occurs on a regular basis in cells throughout the human body.
BRCA mutations are aberrant abnormalities in these genes that are handed down from one generation to the next. When a person has a BRCA mutation, their body is less able to repair ordinary DNA damage to cells. This cumulative cell damage could pave the way for cancer to develop. A person with a BRCA1 or BRCA2 mutation or both is more likely to develop cancers of the breast, ovaries, prostate, or pancreatic, as well as melanoma. Other gene mutations and other factors can influence a person's breast cancer risk.
BRCA gene mutations are found in just 3% to 5% of all breast cancer patients. BRCA mutations, on the other hand, are more common among patients with triple-negative breast cancer (TNBC), Ashkenazi Jewish heritage, a significant family history of breast and/or ovarian cancer, and younger women with breast cancer.
Read more How long does your period last?
Breast cancer types and inherited BRCA mutations
Women with BRCA gene mutations are more likely to develop certain forms of breast cancer.
Breast cancer cells that are fueled by the hormone oestrogen but not by a protein called HER2 are more likely to form in women who have a BRCA2 mutation (human epidermal growth factor 2)
Triple-negative breast cancer (ER-/PR-/HER2-): Women with a BRCA1 mutation are more likely to develop triple-negative breast cancer (ER-/PR-/HER2-) cancer cells that aren't fuelled by estrogen, progesterone, or HER2.
Knowing what causes different types of breast cancer to grow aids scientists in developing novel treatments and clinicians in deciding which medicines to use to delay or stop tumor growth. This frequently necessitates a combination of treatments.
A novel treatment for early-stage BRCA-related breast malignancies has been developed
Women with early-stage breast cancer and hereditary BRCA1/BRCA2 mutations were included in the Olympic trial. Despite normal treatments, they were all at a high risk of breast cancer recurrence.
Participants in the study had received typical breast cancer treatments, including:
a procedure (a mastectomy or lumpectomy)
treatment with chemo (given either before or after surgery)
Endocrine therapy, which is a hormone-blocking medication, is a possibility.
For one year, they were randomly allocated to consume olaparib or placebo (sugar tablets) pills twice a day.
Read more What scientist have Discovered About Estrogen and Physical Activity
Olaparib is a PARP inhibitor, which is a type of medication. PARP (poly adenosine diphosphate-ribose polymerase) is a DNA-repair enzyme. When this enzyme is blocked in BRCA-mutated cancer cells, the cells perish due to increased DNA damage.
The New England Journal of Medicine published the findings of this investigation. Women who got olaparib were less likely than those who received a placebo to have their breast cancer relapse or metastasis (spread to other organs or tissues). After two and a half years of follow-up, slightly more than 85 percent of women who took olaparib were alive and had no cancer recurrence or new second malignancy, compared to 77 percent of women who received placebo.
In addition, the researchers calculated that after three years:
With olaparib, the chances of cancer not spreading to distant organs or tissues where roughly 88 percent, compared to 80 percent with placebo.
The olaparib-treated group had a 92 percent chance of survival, while the placebo group had an 88 percent chance.
Low white cell count, low red cell count, and weariness are all adverse effects of olaparib. These had a slim possibility of coming to fruition.
The bottom line
The FDA has already approved Olaparib for the treatment of BRCA-related malignancies of the ovaries, pancreatic, and prostate, as well as metastatic breast cancer. Based on the findings of this study, FDA clearance for BRCA-related early-stage breast cancer is expected soon. These findings show that taking olaparib for a year after finishing standard therapy could be a suitable option for women with early-stage breast cancer who have an inherited BRCA gene mutation and are at high risk of cancer recurrence and metastasis.
© 2024. All rights reserved.
Our aim is to offer better technology to healthcare providers who in turn can provide better care for the health seekers.
Just go to the S10.Clinic website and click on the "Book appointment" button on the homepage of the website/app, select a specialty and find the doctor of your choice. Once you select a doctor, you can click on the "Consult Online" button to select your preferred date and time.
Once you select the date and time all you have to do is sign up / login to the platform and make the payment online using your credit / debit card on the Razor pay or CC Avenue gateway. Then, you will receive the consultation link via sms / email.
Our online consultation platform is optimized for the following browsers: Google Chrome and Safari. Please ensure you are free 10 minutes prior to your appointment.
All you have to do is find a well light and quiet place with good internet connectivity, preferably a place with Wi-Fi access. Switch on your microphone (for laptop / mobile and allow browser to access it).
Please note: If you are not able to open the link please delete your browser history and cache files of your browser and try again.
This may happen due to poor internet connectivity. In such cases, please check your internet connection and if the issue persists, please reach out to us at onlineconsulting@s10.clinic with the screenshot of the error and we will get this checked from our end. You can also call us at 044-40510510.
Please note: Please ensure you have given access to your audio and video to your browser in the settings panel.
You will receive an email after the online consultation with the following - Provisional diagnosis, visit notes, prescription and follow up.
Yes. The prescription generated during the online consultation is as good as a physical prescription and will be valid for 6 months from the date of issue (as per government regulations).
You will be able to speak and interact with the doctor only for the time he has specified.
Yes. The e-prescription will be valid for offline pharmacies as well.
Safety of your data is our top priority. We have multi-level security checks, multiple data backups, and stringent policies in place to ensure your data remains safe and secure. Additionally, we are a HIPAA compliant company and we take data privacy and security very seriously. All data on S10.Clinic is secured with 256-bit encryption.
All the patients who use the S10.Clinic platform will be called and verified by our support squad before their consultation with the doctors.
You don't have to worry about it. In that case an automatic refund is initiated from our end, and it will reflect in your bank account within 6-7 business days.
Or you can reach out to us at 044-40510510 or onlineconsulting@s10.clinic and we will be happy to help you.
Don't worry if you've missed the online call with the, you can easily reschedule the call with your preferred doctor 10 minutes prior to any consultation. All you have to do is click on the "Reschedule" option in the appointment email.
Or you can reach out to us at 044-40510510 and we can book the same for you.
Please note: If you do not show up or miss an appointment after your appointment time, you won't be able to reschedule it.
You can reschedule any appointment you make 10 minutes before the consultation free of cost. If you want to reschedule any appointment after the consultation time has started you will have to book a new appointment with your preferred doctor. No refund will be offered in such cases.
After the online consultation you will receive a feedback form where you can rate your experience and tell us what went well, what we need to work on. We take your feedback very seriously and this helps us to improve our app and our services.
We're always there for you! You can reach out to our Support Squad at 044-40510510 or send us an email at onlineconsulting@s10.clinic. You can also dm us on Facebook we will be happy to assist you.
Comments